Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PIPE-791 · 3 trials · 11 indications
The number of subjects with TEAEs will be summarized in each treatment arm and compared within each treatment period.
Number of participants with TEAEs
| Arm | Type | Description |
|---|---|---|
| Active followed by Placebo | EXPERIMENTAL | - |
| Placebo followed by Active | EXPERIMENTAL | - |
| Healthy volunteers, brain PET imaging | EXPERIMENTAL | - |
| Healthy volunteers, lung PET imaging | EXPERIMENTAL | - |
| Volunteers with PrMS | EXPERIMENTAL | - |
| Volunteers with IPF | EXPERIMENTAL | - |
| PIPE-791 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PIPE-791 | DRUG | PIPE-791 tablet, taken once daily for 4 weeks |
| Placebo | DRUG | Placebo tablet, taken once daily for 4 weeks |
Key Inclusion Criteria * Male or female 18 to 70 years of age, inclusive, at the first Screening visit. * Only one of the following chronic pain diagnoses at least 6 months prior to Screening: * Osteoarthritis of the knee OR low back pain (with or without painful lumbosacral radiculopathy) * Plain ...
PIPE-791 is an investigational small molecule being developed for Idiopathic Pulmonary Fibrosis (IPF), Multiple Sclerosis, and Chronic Osteoarthritis Pain. It is currently in Phase 1 clinical development and is not yet approved by the FDA.
PIPE-791 is a small molecule being developed by Contineum Therapeutics. Its specific molecular target has not been disclosed in available clinical trial information. The drug is being studied for its potential effects in IPF, Multiple Sclerosis, and chronic pain conditions.
PIPE-791 is being developed by Contineum Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol CTNM. The company is conducting Phase 1 clinical trials to evaluate the drug's safety and tolerability.
PIPE-791 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. Clinical trials have been completed to evaluate safety, tolerability, and other early-stage parameters in healthy volunteers and patient populations.
PIPE-791 has been studied in three completed Phase 1 trials: NCT05983939 evaluated safety and tolerability in healthy volunteers, NCT06683612 was a PET study in healthy volunteers and those with progressive MS and IPF, and NCT06810245 studied the drug in chronic osteoarthritis pain and chronic low back pain.
PIPE-791 is the primary name used in clinical trials and by its developer, Contineum Therapeutics. No alternative names have been reported in the available clinical trial information, so it is not known to be the same as any other marketed or investigational drug.